JP2007532496A - ジフェニルオキソ−インドール−２−オン化合物および癌の処置におけるそれらの使用 - Google Patents

ジフェニルオキソ−インドール−２−オン化合物および癌の処置におけるそれらの使用 Download PDF

Info

Publication number
JP2007532496A
JP2007532496A JP2007506660A JP2007506660A JP2007532496A JP 2007532496 A JP2007532496 A JP 2007532496A JP 2007506660 A JP2007506660 A JP 2007506660A JP 2007506660 A JP2007506660 A JP 2007506660A JP 2007532496 A JP2007532496 A JP 2007532496A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
amino
hydroxy
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007506660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007532496A5 (enExample
Inventor
ヤーコプ・フェルディング
ハンス・クリスティアン・ペダーセン
クリスティアン・クロッグ−イェンセン
モーテン・プレステゴー
スティーブン・ピーター・ブッチャー
ヴィゴ・リンデ
トーマス・スティーブン・クールター
クリスティアン・モンタルベッティ
モハメド・ウディン
セルジュ・レグニエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onxeo DK
Original Assignee
Topotarget AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget AS filed Critical Topotarget AS
Publication of JP2007532496A publication Critical patent/JP2007532496A/ja
Publication of JP2007532496A5 publication Critical patent/JP2007532496A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007506660A 2004-04-08 2005-04-08 ジフェニルオキソ−インドール−２−オン化合物および癌の処置におけるそれらの使用 Pending JP2007532496A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200400576 2004-04-08
DKPA200400693 2004-05-01
DKPA200401153 2004-07-27
DKPA200401216 2004-08-11
PCT/DK2005/000244 WO2005097107A2 (en) 2004-04-08 2005-04-08 Diphenyl - indol-2-on compounds and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2007532496A true JP2007532496A (ja) 2007-11-15
JP2007532496A5 JP2007532496A5 (enExample) 2008-05-22

Family

ID=34965522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007506660A Pending JP2007532496A (ja) 2004-04-08 2005-04-08 ジフェニルオキソ−インドール−２−オン化合物および癌の処置におけるそれらの使用

Country Status (15)

Country Link
US (1) US20070299102A1 (enExample)
EP (1) EP1734951A2 (enExample)
JP (1) JP2007532496A (enExample)
KR (1) KR20060130781A (enExample)
CN (1) CN1953747A (enExample)
AU (1) AU2005230232A1 (enExample)
BR (1) BRPI0509745A (enExample)
CA (1) CA2562399A1 (enExample)
CR (1) CR8673A (enExample)
EA (1) EA013209B1 (enExample)
EC (1) ECSP066913A (enExample)
IL (1) IL178012A0 (enExample)
NO (1) NO20065034L (enExample)
NZ (1) NZ550222A (enExample)
WO (1) WO2005097107A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2555812A1 (en) * 2004-02-13 2005-09-01 President And Fellows Of Harvard College 3-3-di-substituted-oxindoles as inhibitors of translation initiation
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
EP1946120A2 (en) * 2005-10-18 2008-07-23 George Mason Intellectual Properties, Inc. Mtor pathway theranostic
MX2009003875A (es) * 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados y compuestos relacionados de espiro(furo[3,2-c]piridina- 3,3'-indol)-2' (1'h)ona para el tratamiento de enfermedades mediadas por los canales de sodio, tal como dolor.
JP2010522690A (ja) * 2006-10-12 2010-07-08 ゼノン・ファーマシューティカルズ・インコーポレイテッド 三環式スピロオキシインドール誘導体および治療薬としてのその使用
MX2009003876A (es) 2006-10-12 2009-05-11 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos.
JP2010512355A (ja) * 2006-12-11 2010-04-22 トポターゲット・アクティーゼルスカブ 癌の処置のためのジフェニルオキシ−インドール−２−オン化合物のプロドラッグ
JP2010525024A (ja) * 2007-04-24 2010-07-22 トポターゲット・アクティーゼルスカブ 置換３−（４−ヒドロキシフェニル）−インドリン−２−オン化合物
GEP20125664B (en) 2008-02-26 2012-10-10 Takeda Pharmaceuticals Co Condensed heterocyclic derivatives and application thereof
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
PT2350090E (pt) 2008-10-17 2015-11-13 Xenon Pharmaceuticals Inc Composto espiro-oxindol e suas utilizações como agentes terapêuticos
WO2010045197A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2010109008A1 (en) 2009-03-26 2010-09-30 Topotarget A/S Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20121350A1 (es) 2009-10-14 2012-10-20 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
KR20120095402A (ko) 2009-10-23 2012-08-28 파나셀라 랩스, 아이엔씨. 안드로겐 수용체 양성 암의 치료 방법
PE20121699A1 (es) 2010-02-26 2012-12-22 Xenon Pharmaceuticals Inc Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica
AU2014207272A1 (en) * 2013-01-18 2015-07-30 Neal D. Andruska Estrogen receptor inhibitors
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
SG11201600525XA (en) 2013-08-12 2016-02-26 Tokai Pharmaceuticals Inc Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP3094314B1 (en) 2014-01-16 2021-06-23 MUSC Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
EP3749302B1 (en) * 2018-02-08 2024-10-23 The United States of America, as represented by the Secretary, Department of Health and Human Services Oxyphenisatin acetate, oxyphenisatin and bisacodyl for treating triple-negative breast cancer
EA202190146A1 (ru) * 2018-07-03 2021-04-27 Те Борд Оф Трастиз Оф Те Юниверсити Оф Иллинойс Активаторы реакции на несложенные белки
EP3912625A1 (en) * 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途
CN119019312B (zh) * 2024-10-24 2025-01-28 苏州宜联生物医药有限公司 一种吲哚-2-酮衍生物、其抗体药物偶联物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4862753A (enExample) * 1971-12-02 1973-09-01
JPS50154242A (enExample) * 1974-05-18 1975-12-12
JPS5590943A (en) * 1978-12-28 1980-07-10 Fuji Photo Film Co Ltd Photosensitive material and image forming method applicable thereto
JP2002543183A (ja) * 1999-05-04 2002-12-17 ワイス プロゲステロンアンタゴニストとしてのインドリン誘導体
WO2003078394A1 (en) * 2002-03-15 2003-09-25 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
JP2007522234A (ja) * 2004-02-13 2007-08-09 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 翻訳開始阻害剤としての３−３−二置換オキシインドール

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3510730A1 (de) * 1985-03-08 1986-09-11 Möve-Werk GmbH & Co KG, 7410 Reutlingen Verfahren zur herstellung eines baumwollgewebes
US6800658B2 (en) * 1997-11-20 2004-10-05 Children's Medical Center Corporation Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation
IL136227A (en) * 1997-11-20 2005-09-25 Harvard College Pharmaceutical compositions comprising substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnornal cell proliferation and some such novel compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4862753A (enExample) * 1971-12-02 1973-09-01
JPS50154242A (enExample) * 1974-05-18 1975-12-12
JPS5590943A (en) * 1978-12-28 1980-07-10 Fuji Photo Film Co Ltd Photosensitive material and image forming method applicable thereto
JP2002543183A (ja) * 1999-05-04 2002-12-17 ワイス プロゲステロンアンタゴニストとしてのインドリン誘導体
WO2003078394A1 (en) * 2002-03-15 2003-09-25 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
JP2007522234A (ja) * 2004-02-13 2007-08-09 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 翻訳開始阻害剤としての３−３−二置換オキシインドール

Also Published As

Publication number Publication date
AU2005230232A1 (en) 2005-10-20
BRPI0509745A (pt) 2007-09-25
CA2562399A1 (en) 2005-10-20
WO2005097107A3 (en) 2006-03-30
WO2005097107A8 (en) 2006-02-16
KR20060130781A (ko) 2006-12-19
ECSP066913A (es) 2007-02-28
NZ550222A (en) 2010-09-30
EA200601879A1 (ru) 2007-04-27
NO20065034L (no) 2006-11-02
CN1953747A (zh) 2007-04-25
EP1734951A2 (en) 2006-12-27
CR8673A (es) 2007-07-19
US20070299102A1 (en) 2007-12-27
WO2005097107A2 (en) 2005-10-20
EA013209B1 (ru) 2010-04-30
IL178012A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
JP2007532496A (ja) ジフェニルオキソ−インドール−２−オン化合物および癌の処置におけるそれらの使用
JP7037679B2 (ja) 新規の二環式ブロモドメイン阻害剤
CN112601750B (zh) Ptpn11（shp2）抑制剂
JP5102839B2 (ja) 有糸分裂進行を阻害するための化合物
TW591030B (en) Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
EA005996B1 (ru) Пирролзамещенный 2-индолинон, фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
JP2002522452A (ja) 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン
AU2005237788A1 (en) Indole and azaindole derivatives with antitumor action
JP2015051999A (ja) 新しい治療用作用物質
KR20030024661A (ko) 2-아실 인돌 유도체 및 항종양제로서의 이의 용도
TW200916458A (en) Heterocyclic compounds and methods of use thereof
EA028175B1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
JP2010520881A (ja) 黒色腫の処置
TW200529846A (en) 3-quinolinecarbonitrile protein kinase inhibitors
KR20220143116A (ko) 조합 요법을 포함하는 setd2 억제제 및 관련 방법 및 용도
EP2513089B1 (en) 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
EP2655359B1 (en) Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
TW200930716A (en) Synthesis of 8H-3a-aza-cyclopenta[a]indenes and 5,10-dihydropyrrolo[1,2-b]isoquinolines derivatives and their use as antitumor therapeutic agents
HK1106141A (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
MXPA06010822A (en) Diphenyl ox-indol-2-on compounds and their use in the treatment of cancer
ZA200608044B (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
JPWO2021168313A5 (enExample)
Mokhtari et al. Synthesis of 3-Arylidene and 3-Arylimine Oxindole Derivatives and Evalu-ation of Their Src Kinase Inhibitory and Antiproliferative Activities
WO2020147582A1 (zh) 环烷基取代的酰胺类衍生物、其制法与医药上的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110906

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111012

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111019

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120221